Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William G. Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis
Institutions: University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The Ohio State University, Memorial Sloan Kettering Cancer Center, University of Chicago, University of Chicago Medical Center, Huntsman Cancer Institute, Winship Cancer Institute, Emory University, University of California, Los Angeles, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Mayo Clinic, Mayo Clinic in Florida, University of Kansas, The University of Texas Southwestern Medical Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center, University of Florida, Oregon Health & Science University, Foundation Medicine (United States), Blood Cancer United, OHSU Knight Cancer Institute, University of Cincinnati
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3214567790